caa a22 4500 477058167 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203776 doi (NATIONALLICENCE)springer-10.1007/BF00203776 Effects of single oral doses of lysine clonixinate and acetylsalicylic acid on platelet functions in man [Elektronische Daten] [D. Pallapies, A. Muhs, L. Bertram, G. Rohleder, P. Nagyiványi, B. Peskar] Lysine clonixinate is an analgesic drug with a so far unknown mechanism of action. We have determined its effect on platelet cyclooxygenase in man. Biosynthesis of thromboxane (TX)B2 and prostaglandin (PG)F2α in clotting whole blood ex vivo as well as collagen-induced platelet aggregation measured before and at various time points after oral administration of 125 mg lysine clonixinate were compared to results obtained with 500 mg acetylsalicylic acid (ASA). While biosynthesis of both TXB2 and PGF2α measured radioimmunologically was inhibited significantly 2.5 h, but not 6 h, after administration of lysine clonixinate, inhibition by ASA was much greater and still highly significant after 48 h. Similarly, collagen-induced aggregation of platelet-rich plasma was inhibited for a longer period and to a greater extent after administration of ASA than after lysine clonixinate. Our results indicate that lysine clonixinate is a cyclooxygenase inhibitor of moderate potency. It remains to be investigated whether mechanisms other than inhibition of cyclooxygenase contribute to the analgesic activity of lysine clonixinate. Springer-Verlag, 1996 Lysine clonixinate nationallicence Acetylsalicylic acid nationallicence Analgesia nationallicence platelet aggregation nationallicence thromboxane B2 nationallicence prostaglandin F2α nationallicence Pallapies D. Department of Pharmacology and Toxicology, Ruhr University, Universitätsstrasse 150, D-44801, Bochum, Germany aut Muhs A. Department of Pharmacology and Toxicology, Ruhr University, Universitätsstrasse 150, D-44801, Bochum, Germany aut Bertram L. Department of Pharmacology and Toxicology, Ruhr University, Universitätsstrasse 150, D-44801, Bochum, Germany aut Rohleder G. Roemmers S.A.I.C.F., Buenos Aires, Argentina aut Nagyiványi P. Roemmers S.A.I.C.F., Buenos Aires, Argentina aut Peskar B. Department of Experimental and Clinical Pharmacology, University of Graz, Universitätsplatz 4, A-8010, Graz, Austria aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 351-354 0031-6970 49:5<351 1996 49 228 https://doi.org/10.1007/BF00203776 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203776 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pallapies D. Department of Pharmacology and Toxicology, Ruhr University, Universitätsstrasse 150, D-44801, Bochum, Germany aut NATIONALLICENCE 700 1- Muhs A. Department of Pharmacology and Toxicology, Ruhr University, Universitätsstrasse 150, D-44801, Bochum, Germany aut NATIONALLICENCE 700 1- Bertram L. Department of Pharmacology and Toxicology, Ruhr University, Universitätsstrasse 150, D-44801, Bochum, Germany aut NATIONALLICENCE 700 1- Rohleder G. Roemmers S.A.I.C.F., Buenos Aires, Argentina aut NATIONALLICENCE 700 1- Nagyiványi P. Roemmers S.A.I.C.F., Buenos Aires, Argentina aut NATIONALLICENCE 700 1- Peskar B. Department of Experimental and Clinical Pharmacology, University of Graz, Universitätsplatz 4, A-8010, Graz, Austria aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 351-354 0031-6970 49:5<351 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer